# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

**SCHEDULE 13G** (RULE 13D - 102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

(Amendment No. )\*

<u>Catalyst Biosciences, Inc.</u> (Name of Issuer)

Common Stock, \$0.001 par value (Title of Class of Securities)

<u>14888D208</u> (CUSIP Number)

<u>December 20, 2017</u> (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[] Rule 13d-1(b)

[x] Rule 13d-1(c)

[] Rule 13d-1(d)

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see the Notes*).

<sup>\*</sup>The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

	PN, IA
12.	TYPE OF REPORTING PERSON
	5.4%
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []
	311,175
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	311,175
8.	SHARED DISPOSITIVE POWER
	0
7.	SOLE DISPOSITIVE POWER
	311,175
6.	SHARED VOTING POWER
	0
5.	SOLE VOTING POWER
NUMBER	OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
	Delaware
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
3.	SEC USE ONLY
	(a) [ ] (b) [ ]
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	Nexthera Capital LP
1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)				
	Nexthera Capital GP LLC				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
	(a) [ ] (b) [ ]				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
NUMBER (	OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:				
5.	SOLE VOTING POWER				
	0				
6.	SHARED VOTING POWER				
	311,175				
7.	SOLE DISPOSITIVE POWER				
	0				
8.	SHARED DISPOSITIVE POWER				
	311,175				
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	311,175				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	5.4%				
12.	TYPE OF REPORTING PERSON				
	00				

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Daniel Malek
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
	(a) [] (b) []
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	Belgium
NUMBE	CR OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
5.	SOLE VOTING POWER
	0
6.	SHARED VOTING POWER
	311,175
7.	SOLE DISPOSITIVE POWER
	0
8.	SHARED DISPOSITIVE POWER
	311,175
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	311,175
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	5.4%
12.	TYPE OF REPORTING PERSON
	IN

1.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)			
	Ori Hershkovitz			
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
	(a) [] (b) []			
3.	SEC USE ONLY			
4.	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Israel			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:				
5.	SOLE VOTING POWER			
	0			
6.	SHARED VOTING POWER			
	311,175			
7.	SOLE DISPOSITIVE POWER			
	0			
8.	SHARED DISPOSITIVE POWER			
	311,175			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	311,175			
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES []			
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	5.4%			
12.	TYPE OF REPORTING PERSON			
	IN			

## Item 1(a). Name of Issuer:

Catalyst Biosciences, Inc. (the "Issuer").

#### Item 1(b). Address of Issuer's Principal Executive Offices:

260 Littlefield Avenue South San Francisco, California 94080

### Item 2(a). Name of Persons Filing:

This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):

- i) Nexthera Capital LP ("Nexthera Capital");
- ii) Nexthera Capital GP LLC ("Nexthera GP");
- iii) Daniel Malek ("Mr. Malek"); and
- iv) Ori Hershkovitz (Mr. Hershkovitz").

Nexthera GP is the general partner of Nexthera Capital. Mr. Malek and Mr. Hershkovitz are the managing members Nexthera GP By virtue of these relationships, each of Nexthera GP, Mr. Malek and Mr. Hershkovitz may be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) beneficially owned by Nexthera Capital.

### Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is 900 Third Avenue, Suite 201.1, New York, New York 10022.

### Item 2(c). Citizenship:

- i) Nexthera Capital is a Delaware limited partnership;
- ii) Nexthera GP is a Delaware limited liability company;
- iii) Mr. Malek is a citizen of Belgium; and
- iv) Mr. Hershkovitz is a citizen of Israel.

#### Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share (the "Common Stock")

## Item 2(e). CUSIP Number:

14888D208

Item 3.			If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:			
	(a)	[]	Broker (	or dealer registered under Section 15 of the Exchange Act.		
	(b)	[]	Bank as defined in Section 3(a)(6) of the Exchange Act.			
	(c)	[]	Insuranc	ce company defined in Section 3(a)(19) of the Exchange Act.		
	(d)	[]	Investm	ent company registered under Section 8 of the Investment Company Act.		
	(e)	[]	An inve	stment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).		
	(f)	[]	An emp	loyee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).		
	(g)	[]	A paren	t holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).		
	(h)	[]	A savin	gs association as defined in Section 3(b) of the Federal Deposit Insurance Act.		
	(i)	[]	A churc	h plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;		
	(j)	[]	Group,	in accordance with Rule 13d-1(b)(1)(ii)(J).		
Item 4.	Ownership.					
	Prov	vide	the followi	ng information regarding the aggregate number and percentage of the class of securities of the Issuer.		
	(a)		Amount beneficially owned:			
	As of the close of business on December 26, 2017, the Reporting Persons may be deemed to Common Stock.			close of business on December 26, 2017, the Reporting Persons may be deemed to have beneficially owned 311,175 shares of Stock.		
	(b)		Percent of class:			
		Common Stock outstanding as of December 20, 2017, which is the total number of Common Stock outstandin Prospectus Supplement on Form 424B5 filed with the Securities and Exchange Commission on December 2		gate percentage of Common Stock reported owned by each person named herein is based upon approximately 5,813,780 shares of Stock outstanding as of December 20, 2017, which is the total number of Common Stock outstanding as reported in the Issuer's Supplement on Form 424B5 filed with the Securities and Exchange Commission on December 21, 2017. As of the close of December 26, 2017, the Reporting Persons may be deemed to have beneficially owned approximately 5.4% of the outstanding Stock.		
	(c)		Number of shares as to which such person has:			
			(i) S	sole power to vote or to direct the vote:		
			S	see Cover Pages Items 5-9.		
			(ii) S	chared power to vote or to direct the vote		
			S	See Cover Pages Items 5-9.		
			(iii) S	sole power to dispose or to direct the disposition of		
			S	see Cover Pages Items 5-9.		
			(iv) S	shared power to dispose or to direct the disposition of		
			S	see Cover Pages Items 5-9.		

## Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

## Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not applicable.

### Item 8. Identification and Classification of Members of the Group.

See Exhibit A.

### Item 9. Notice of Dissolution of Group.

Not applicable.

#### Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

### **SIGNATURES**

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

December 27, 2017 NEXTHERA CAPITAL LP

Date:

Date:

Date:

December 27, 2017

By: Nexthera Capital GP LLC, its general partner

By: <u>/s/ Daniel Malek</u>
Name: Daniel Malek
Title: Managing Member

NEXTHERA CAPITAL LP

By: Nexthera Capital GP LLC, its general partner

By: <u>/s/ Daniel Malek</u>
Name: Daniel Malek
Title: Managing Member

December 27, 2017 DANIEL MALEK

By: <u>/s/ Daniel Malek</u> Name: Daniel Malek

Date: December 27, 2017 ORI HERSHKOVITZ

By: <u>/s/ Ori Hershkovitz</u> Name: Ori Hershkovitz

#### **EXHIBIT A**

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock, par value \$0.001 per share, of Catalyst Biosciences, Inc., dated as of December 27, 2017 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: December 27, 2017 NEXTHERA CAPITAL LP

By: Nexthera Capital GP LLC, its general partner

By: /s/ Daniel Malek Name: Daniel Malek

Title: Managing Member

NEXTHERA CAPITAL LP

By: Nexthera Capital GP LLC, its general partner

By: /s/ Daniel Malek Name: Daniel Malek Title: Managing Member

DANIEL MALEK

By: /s/ Daniel Malek Name: Daniel Malek

ORI HERSHKOVITZ

By: /s/ Ori Hershkowvitz Name: Ori Hershkovitz

Date:

Date:

December 27, 2017

December 27, 2017

December 27, 2017 Date: